奥美拉唑可改善伴有胃食管反流的哮喘患者的呼气峰值流速和生活质量。

Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux.

作者信息

Levin T R, Sperling R M, McQuaid K R

机构信息

Department of Medicine, San Francisco Veteran's Affairs Medical Center, California, USA.

出版信息

Am J Gastroenterol. 1998 Jul;93(7):1060-3. doi: 10.1111/j.1572-0241.1998.329_q.x.

DOI:10.1111/j.1572-0241.1998.329_q.x

PMID:9672330

Abstract

OBJECTIVE

The aim of this study was to determine if omeprazole improves pulmonary function and quality of life in asthmatics with gastroesophageal reflux.

METHODS

This was a double blind, randomized, placebo-controlled cross-over trial. After a 4-wk lead-in period, nine patients with documented asthma and gastroesophageal reflux, were prescribed either omeprazole 20 mg, daily or placebo for 8 wk and then crossed over to the alternate treatment. Outcome measurements included: forced expiratory volume at 1 s (FEV1), peak expiratory flow rate (PEFR), and responses on the Asthma Quality of Life Questionnaire, a validated disease specific measure of functional status.

RESULTS

After omeprazole treatment, compared with placebo, patients had higher mean morning and evening PEFR, mean absolute difference (95% CI): morning: 37.8 L/min. (10.9-64.6), evening: 31.2 (3.2-59.2). Omeprazole treatment led to higher mean overall scores on the Asthma Quality of Life Questionnaire, and on the subdomains of activity limitation, symptoms, and emotions (p = 0.039, 0.049, 0.024, 0.040). A trend toward higher FEV1 (mean: 15.6% difference) with omeprazole failed to reach statistical significance (p > 0.2).

CONCLUSIONS

After taking omeprazole for 8 wk, asthmatics with GER have better PEFR and quality of life than after placebo.

摘要

目的

本研究旨在确定奥美拉唑是否能改善伴有胃食管反流的哮喘患者的肺功能和生活质量。

方法

这是一项双盲、随机、安慰剂对照的交叉试验。在为期4周的导入期后，9名有哮喘和胃食管反流记录的患者，被给予每日20毫克奥美拉唑或安慰剂，为期8周，然后交叉接受替代治疗。结果测量包括：第1秒用力呼气量（FEV1）、呼气峰值流速（PEFR），以及哮喘生活质量问卷的反应，这是一种经过验证的针对功能状态的疾病特异性测量方法。

结果

与安慰剂相比，奥美拉唑治疗后，患者的平均早晚PEFR更高，平均绝对差异（95%CI）：早晨：37.8升/分钟（10.9 - 64.6），晚上：31.2（3.2 - 59.2）。奥美拉唑治疗使哮喘生活质量问卷的平均总分以及活动受限、症状和情绪子领域的得分更高（p = 0.039、0.049、0.024、0.040）。奥美拉唑使FEV1有升高趋势（平均差异：15.6%），但未达到统计学显著性（p > 0.2）。